Initial Features of 605 Patients With NHL and Kaplan Meier Estimate of Probability of CNS Recurrence at 1 Year After Diagnosis
| . | N (%) . | Probability of CNS Recurrence (95% CI) . | P* . |
|---|---|---|---|
| Age (yr) | |||
| ≤60 | 375 (62) | 4.4 (4.3-4.5) | .46 |
| >60 | 230 (38) | 4.8 (4.6-5.0) | |
| Sex | |||
| Male | 347 (57.3) | 5.2 (5.1-5.3) | .19 |
| Female | 258 (42.6) | 4.5 (4.4-4.6) | |
| Histology | |||
| DLCL | 537 (88.7) | 4.2 (4.1-4.3) | .3 |
| FLCL | 58 (9.5) | 7.7 (7.4-8.0) | |
| DMCL | 8 (1) | 0 | |
| Phenotype | |||
| B | 300 | 7.0 (6.8-7.2) | .008 |
| T | 23 | 4.8 (4.3-5.2) | |
| Unknown | 282 | ||
| LDH | |||
| Elevated | 318 (52.6) | 9.8 (9.7-9.9) | .0000 |
| Normal | 277 (45.7) | 1.1 (1.0-1.2) | |
| Unknown | 10 (1.6) | ||
| B2 microglobulin | |||
| Elevated (>3) | 140 (23.1) | 8.7 (8.4-9.1) | .012 |
| Normal (<3) | 398 (65.7) | 4.7 (4.6-4.8) | |
| Unknown | 67 (11.1) | ||
| Stage | |||
| I-II | 294 (48.6) | 2.2 (2.1-2.3) | .0014 |
| III | 87 (14.3) | 3.0 (2.8-3.2) | |
| IV | 217 (35.9) | 9.0 (8.8-9.2) | |
| Unknown | 7 (1) | ||
| B symptoms | |||
| Yes | 191 (31.6) | 8.6 (8.4-8.8) | .0037 |
| No | 408 (67.4) | 2.8 (2.7-2.9) | |
| Unknown | 6 (1) | ||
| Performance status | |||
| 0-1 | 488 (80.6) | 3.3 (3.2-3.4) | .0005 |
| >1 | 96 (15.8) | 13.2 (12.8-13.6) | |
| Unknown | 21 (3.4) | ||
| Extranodal sites | |||
| 0-1 | 480 (79.3) | 2.8 (2.7-2.9) | .0000 |
| >1 | 119 (19.7) | 13.3 (12.9-13.7) | |
| Unknown | 7 (1) | ||
| International index | |||
| Low (0-1) | 257 (42.4) | 0.8 (0.7-0.9) | .0000 |
| Low intermediate (2) | 141 (22.5) | 6.5 (6.3-6.7) | |
| High intermediate (3) | 121 (20) | 7.8 (7.6-8.0) | |
| High (4-5) | 60 (10.0) | 11.6 (5.7-17.5) | |
| Unknown | 41 (6.7) | ||
| Treatment (for details, see text) | |||
| CHOP-Bleo/OPEN | 217 (35.9) | 1.5 (0.5-2.5) | .003 |
| Alternating triple therapy | 388 (64.1) | 6.5 (6.4-6.6) |
| . | N (%) . | Probability of CNS Recurrence (95% CI) . | P* . |
|---|---|---|---|
| Age (yr) | |||
| ≤60 | 375 (62) | 4.4 (4.3-4.5) | .46 |
| >60 | 230 (38) | 4.8 (4.6-5.0) | |
| Sex | |||
| Male | 347 (57.3) | 5.2 (5.1-5.3) | .19 |
| Female | 258 (42.6) | 4.5 (4.4-4.6) | |
| Histology | |||
| DLCL | 537 (88.7) | 4.2 (4.1-4.3) | .3 |
| FLCL | 58 (9.5) | 7.7 (7.4-8.0) | |
| DMCL | 8 (1) | 0 | |
| Phenotype | |||
| B | 300 | 7.0 (6.8-7.2) | .008 |
| T | 23 | 4.8 (4.3-5.2) | |
| Unknown | 282 | ||
| LDH | |||
| Elevated | 318 (52.6) | 9.8 (9.7-9.9) | .0000 |
| Normal | 277 (45.7) | 1.1 (1.0-1.2) | |
| Unknown | 10 (1.6) | ||
| B2 microglobulin | |||
| Elevated (>3) | 140 (23.1) | 8.7 (8.4-9.1) | .012 |
| Normal (<3) | 398 (65.7) | 4.7 (4.6-4.8) | |
| Unknown | 67 (11.1) | ||
| Stage | |||
| I-II | 294 (48.6) | 2.2 (2.1-2.3) | .0014 |
| III | 87 (14.3) | 3.0 (2.8-3.2) | |
| IV | 217 (35.9) | 9.0 (8.8-9.2) | |
| Unknown | 7 (1) | ||
| B symptoms | |||
| Yes | 191 (31.6) | 8.6 (8.4-8.8) | .0037 |
| No | 408 (67.4) | 2.8 (2.7-2.9) | |
| Unknown | 6 (1) | ||
| Performance status | |||
| 0-1 | 488 (80.6) | 3.3 (3.2-3.4) | .0005 |
| >1 | 96 (15.8) | 13.2 (12.8-13.6) | |
| Unknown | 21 (3.4) | ||
| Extranodal sites | |||
| 0-1 | 480 (79.3) | 2.8 (2.7-2.9) | .0000 |
| >1 | 119 (19.7) | 13.3 (12.9-13.7) | |
| Unknown | 7 (1) | ||
| International index | |||
| Low (0-1) | 257 (42.4) | 0.8 (0.7-0.9) | .0000 |
| Low intermediate (2) | 141 (22.5) | 6.5 (6.3-6.7) | |
| High intermediate (3) | 121 (20) | 7.8 (7.6-8.0) | |
| High (4-5) | 60 (10.0) | 11.6 (5.7-17.5) | |
| Unknown | 41 (6.7) | ||
| Treatment (for details, see text) | |||
| CHOP-Bleo/OPEN | 217 (35.9) | 1.5 (0.5-2.5) | .003 |
| Alternating triple therapy | 388 (64.1) | 6.5 (6.4-6.6) |
*Fisher-Freeman-Halton exact test.